NANailya Sayfullaevna Asfandiyarova

Nailya Sayfullaevna Asfandiyarova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nailya Sayfullaevna Asfandiyarova has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Psoriatic arthritis (literature review)

    by N. S. Asfandiyarova, R. R. Shilin

    Psoriatic arthritis (PsA) is a chronic immune-inflammatory progressive disease of the musculoskeletal system observed in psoriasis, which affects the joints, spine and entheses; it occurs in the form of arthritis, dactylitis, enthesitis, and can also manifest as spondylitis or sacroiliitis. The etiology of PsA is unknown, but the pathogenesis has been studied in more detail. Under the influence of external factors, such as infectious agents (viruses, bacteria, fungi), neuropsychic stress, injuries, drugs, changes in intestinal microbiota, etc., genetically predisposed individuals experience activation of the immune system, both congenital and acquired. Currently, there are 5 clinical forms of PsA: predominantly lesion of the distal interphalangeal joints of the hands and feet, distal form; mutilating arthritis; psoriatic spondylitis; asymmetric mono-oligoarthritis; symmetrical polyarthritis, rheumatoid-like form. Along with the characteristic symptomsof skin and joint damage, patients with PsA note a decrease in the quality of life, general malaise, fever, enlarged lymph Review nodes, weight loss, signs of comorbid pathology (obesity, diabetes, cardiovascular diseases). Arthritis is accompanied by tendinitis, synovitis, enthesitis. Isolated spinal damage (psoriatic spondylitis) is rare, it is usually combined with peripheral arthritis, characterized by pain in the spine, dysfunction, curvature. Differential diagnostics are carried out with rheumatoid arthritis, gout, ankylosing spondylitis, polyosteoarthritis, infectious forms of joint damage, joint damage in chronic inflammatory bowel diseases. Treatment of PsA should include medication, physiotherapy and spa treatment. Usually, treatment of PsA begins with the use of such drugs as methotrexate, leflunomide, sulfasalazine, cyclosporine A; non-steroidal anti-inflammatory drugs and intra-articular administration of glucocorticosteroids are used as an auxiliary agent, they are classified as symptom-modifying drugs, they partially improve the patient’s quality of life, reduce pain, but have little effect on the progression of the pathological process. In the absence of an effect from previously conducted treatment and contraindications, genetically engineered biological drugs are used.


  • The Effect of Nicotine on Cell-Mediated Immunity in Men with Chronic Obstructive Pulmonary Disease

    by Ryazan State Medical University, Nailya S. Asfandiyarova, Irina B. Ponomareva, Oleg M. Uryas'YEv, Sergey A. Kulikov, Anna N. Ermachkova

    INTRODUCTION: One of common pulmonary diseases associated with tobacco smoking, is chronic obstructive pulmonary disease (COPD). Despite a large number of publications devoted to the problem of COPD, there remain many unclear issues concerning the involvement of the immune system in the development of the disease. The effect of nicotine on cell-mediated immunity in COPD has not been studied in practice. AIM: To study the influence of nicotine on the proliferating activity of lymphocytes of the peripheral blood in response to phytohemagglutinin (PHA) in patients with COPD. MATERIALS AND METHODS: Fifty two patients with COPD were examined. The control group included 32 patients of similar gender and age, without any significant history of smoking and of respiratory diseases. All the patients completed CAT questionnaire and were tested on mMRC scale, and underwent spirometry, examination for the proliferating activity of lymphocytes in response to phytohemagglutinin and for the functional activity of cells synthesizing cyclooxygenase. RESULTS: In patients with COPD, a decrease in the proliferative activity of lymphocytes in response to PHA was found in comparison with this parameter of patients without COPD (50.4 ± 10.2% vs. 55.0 ± 10.2%, p < 0.05), as well as an increase in the activity of cells synthesizing cyclooxygenase (1.2 ± 0.3 vs. 1.0 ± 0.2 p < 0.001). Addition of a combination of nicotine and PHA to cell culture led to a decrease in the proliferative activity of cells in response to mitogen in most patients, and to its increase in a third of patients. CONCLUSION: In patients with COPD with the underlying inflammation, suppression of cell-mediated immune reactions was noted. Nicotine in vitro suppresses the response of lymphocytes to mitogen in most patients, however, in some patients it causes stimulation, the cause of which remains unclear.


  • Open Access

    May be dysfunction of cellular immunity considered a sign of post-COVID syndrome?

    by Nailya S. Asfandiyarova, Mariya A. Rubtsova, Асфандиярова Наиля Сайфуллаевна, Рубцова Мария А.

    Our aim was to study association between proliferative activity of peripheral blood lymphocytes after COVID, and developing post-COVID syndrome, and to determine whether the cell immunity dysfunction may be regarded as its marker. The retrospective cohort study involved 242 patients (56 males, 186 females, 18 to 85 years old) who contracted new coronavirus infection. Of them, post-COVID syndrome was diagnosed in 180 cases (duration over 3 months). The patients were classified by severity of clinical course of COVID (i.e., presence of acute respiratory disease and pneumonias), and PHA-induced blast transformation of lymphocytes. Along with PHA-induced response, we studied cyclooxygenase (COG)-producing cells by morphological method. Control group consisted of 200 healthy people without any features of coronavirus infection. All patients were questioned and examined by multidisciplinary medical team, dependent on their complaints. We also registered incidence of comorbidities associated with cellular immune deficiency. The patients with post-COVID syndrome exhibited a decrease of PHA-induced lymphocyte proliferation as compared with control group (significant at p 0.01 in cases of acute respiratory infection, and p 0.05 in patients with pneumonia). Activity of COG-producing cells was similar in all groups, independently on presence of post-COVID syndrome. Classification of patients by presence of cellular immune dysfunction (PHA-induced blast transformation 50%) allowed to detect higher activity of COG-producing cells. This enzyme is known to participate in development of inflammation promoting immune deficiency, thus, probably, manifesting in clinical activation of herpesvirus infection following COVID-19. Activity of COG-synthesizing cells was found to be higher in post-COVID syndrome which evolves after middle-severe and severe forms of new coronavirus infection complicated by pneumonias. Chronic inflammation in post-COVID syndrome associated with high activity of COG-producing cells may promote dysfunction of cell immunity, thus being a cause of evolving syndrome, like as its biomarker. Absence of the immune cell dysfunction markers among other post-COVID features leads to decreased registration of post-COVID patients and misinterpretation of the results obtained.


  • Open Access

    Risk factors for development of the post-COVID syndrome

    by N. S. Asfandiyarova, E. V. Philippov, O. V. Dashkevich, A. G. Iakubovskaia, K. A. Moseichuk, N. S. Zhuravleva, S. A. Kulikov, E. N. Fedyaeva

    Aim: to study risk factors of development of the post-COVID syndrome (PCS).Material and methods. 210 patients with a history of new coronavirus infection (COVID-19) (47 men, 163 women aged 18–85 years) were examined by doctors of various specialties. Patients were divided into several groups depending on the presence of PCS, as well as the severity of the disease.Results. The risk factors of the PCS development are moderate and severe course of the pathological process in acute period of COVID-19 disease (p 0.001). In women, PCS is seen more often than in men (30 / 135 vs. 17 / 28, p 0 / 001), other risk factors are age over 50 years (p 0.05), polymorbidity (p 0.01), treatment with glucocorticoids in acute disease period (76 / 165 vs. 4 / 45, p 0.001). In cases of mild COVID-19 course, neither age nor polymorbidity increased the risk of PCS development (p 0.05), however a dysfunction of cellular immunity was significant, specifically the proliferative activity of lymphocytes in response to mitogen: 50.6 ± 10.4 % vs. 54.0 ± 5.1 %, p 0.05). In cases of severe COVID-19 course, the gender differences and dysfunction of the cellular immune system are not the determinants for the PCS development (p 0.05), however the age (56.7 ± 13.1 years vs. 42.1 ± 15.4 years, p 0.01) its linkage to somatic pathology (a cardiovascular disease) besides glucocorticoids threatment (64 / 89 vs. 3 / 9, p 0.05) are important risk factors for PCS.Conclusions. The main risk factor for PCS development is the moderate and severe course of the pathological process in the acute period of COVID-19 infection, female gender, age over 50 years, polymorbidity, treatment with glucocorticoids in the disease acute period. In case of mild COVID-19 course, neither age nor the polymorbidity increased the risk of PCS development, but the dysfunction of cellular immunity is significant. In case of severe COVID-19, the gender differences and dysfunction of the cellular immune system are not the determinants for the PCS development, however age, concomitant somatic pathology (a cardiovascular disease) and glucocorticoids treatment in acute period are important risk factors for the PCS development. The titer of protective IgG class antibodies to SARS-CoV-2 is not linked to risk of the PCS development.


  • Benign Hyperbilirubinemia of Gilbert Type

    by Nailya S. Asfandiyarova, Ryazan State Medical University, Alina G. Yakubovskaya

    INTRODUCTION: Benign hyperbilirubinemia of Gilbert type affects 10% of population, most commonly men of 20–30 years of age. In the article, description of a classic clinical case illustrating the course of Gilbert syndrome, is given. After an intercurrent infection, a 32-year old man presented with jaundice with elevation of the level of unconjugated bilirubin against the normal background level of enzymes. Bearing in mind a probability of being excluded from the flight crew, the patient agreed to the puncture biopsy of the liver, and the morphological examination of the hepatic tissue confirmed the diagnosis of benign hyperbilirubinemia of Gilbert type. A molecular genetic examination also showed the existence of tyrosine-arginine repeats in the promotor region of uridine diphosphate–glucuronosyltransferase gene. Adequately selected treatment with phenobarbital stimulating the activity of the enzyme, led to normalization of bilirubin level and to improvement of the patient’s well-being. CONCLUSION: Chronic familial non-hemolytic hyperbilirubinemias are often given insufficient attention not only due to the fact that their outcomes do not pose a serious threat to the patient’s health, and, according to the erroneous opinion, are rare, but to a larger extent due to the fact that the diagnosis presents certain difficulties for a therapist or a general practitioner.


  • Open Access

    Post-COVID-19 syndrome

    by N. S. Asfandiyarova

    The disease caused by new coronavirus infection (COVID-19) is a global problem not only because of its wide spread occurrance, but also due to the high incidence of post-COVID syndrome. The literature review presents the results of numerous observations of patients, who undergone COVID-19. The most common symptoms are: general weakness, impaired cognitive functions, memory loss, depression, anosmia, dysgeusia, shortness of breath, cough, chest pain, abdominal pain, anorexia, nausea, vomiting, diarrhea, less often — alopecia, skin rashes, etc. The most frequent symptoms of the post-COVID syndrome are described; the reasons and risk factors for its development are analyzed. The lack of views sameness on the term “postCOVID syndrome” makes it diffi cult to evaluate the frequency of certain symptoms development. Variants of the post-COVID syndrome are considered. It is proposed to distinguish between the post-COVID syndrome, developed after acute COVID-19 that lasts up to 12 weeks, and a prolonged variant of post-COVID clinical symptoms that last longer than 12 weeks, which should be distinguished from lingering COVID-19, its complications, and the consequences of intensive care. The questions of prognosis, diagnostics, and treatment of post-COVID syndrome are discussed.


  • Open Access

    Clinical manifestations of post-COVID-19 syndrome

    by N.S. Asfandiyarova, E.V. Filippov, V.G. Demikhov, O.V. Dashkevich, A.G. Yakubovskaya, K.A. Moseychuk, N.S. Zhuravleva, S.A. Kulikov

    Aim: to assess the prevalence of various clinical manifestations in COVID-19 survivors, depending on the time interval after the disease, clinical severity, and the presence of polymorbidity. Patients and Methods: the study included 253 patients (187 females and 66 males), 18–85 years old, who survived COVID-19. The patients were split into two groups based on the disease severity during the acute phase: group 1 consisted of patients with mild COVID-19 illness (n=133); group 2 consisted of patients with moderate and severe COVID-19 illness (n=120). In addition, patients of each of the groups were divided into two subgroups, depending on the time elapsed from the acute phase of COVID-19 illness: in subgroups A the health assessment of patients was performed within 3 months (12 weeks) after the acute phase of the diseases and in subgroups B — 3 months (12 weeks) after the disease, i.e. the time interval ranged from 3 months to one year after COVID-19 illness. A multi-stage phone interview of the patients was used to reveal the presence of symptoms. Also, outpatient medical records of those patients who addressed therapists or narrow specialists, were reviewed. Results: symptoms were revealed both in patients of subgroup 1A (45/52 (86.5%)) and subgroup 2А (42/45 (93.3%)), or, in other words, the symptoms were absent in 7 (13.5%) and 3 (6.7%) patients, respectively. Three months after COVID-19 illness, the symptoms were absent in 34 (42%) patients of subgroup 1B and in 13 (17.3%) patients of subgroup 2B (p<0.001), while at least one symptom persisted in 47/81 (58%) patients of subgroup 1B and 62/75 (82%) patients of subgroup 2B. In both patient groups the most common symptoms comprised fatigue, shortness of breath, and cough. In group 2 patients central nervous and cardiovascular system consequences and arthralgia were frequently reported. The prevalence of comorbidities was higher in group 2 patients than that in group 1 patients, and the difference was statistically significant (p < 0.01). Conclusions: the development of post-COVID-19 syndrome does not depend on the illness severity during the acute phase, and it may occur both in mild and moderate or severe cases. However, in the latter category the patients will have more symptoms. In patients recovered from COVID-19, most of the disease sequela were revealed in central nervous, bronchopulmonary, and cardiovascular systems. Comorbidities are associated with the severity of the novel coronavirus disease during the acute phase. COVID-19 survivors need follow-up care during the first three months after the acute phase and in the later period which should be provided by multidisciplinary team of specialists for achieving complete recovery of the patients’ health and improving the quality of life. KEYWORDS: coronavirus infection, COVID-19, post-COVID-19 syndrome, comorbidities, central nervous system disorders, bronchopul - monary system disorders, cardiovascular system disorders. FOR CITATION: Asfandiyarova N.S., Filippov E.V., Demikhov V.G. et al. Clinical manifestations of post-COVID-19 syndrome. Russian Medical Inquiry. 2022;6(11):612–617 (in Russ.). DOI: 10.32364/2587-6821-2022-6-11-612-617.


  • Advantages and disadvantages of lockdown (self-isolation regime) introduced during the first wave of coronaviral infection for patients with polymorbid pathology

    by Nailya S. Asfandiyarova, Evgenii V. Filippov, Ol'GA V. Dashkevich, Natalia V. Doroshina, Ekaterina I. Suchkova, Leonid I. Shehtmester, Асфандиярова Наиля Сайфуллаевна

    AIM: To study the structure of mortality not caused by coronavirus infection, in patients with polymorbid pathology during the period of self-isolation (lockdown). MATERIALS AND METHODS: Outpatient records of 2 423 patients with polymorbid pathology (841 males and 1 582 females, aged from 18 to 99 years) were examined. The mortality and its causes during three years including a period of lockdown were investigated. RESULTS: The overall mortality rate among patients with polymorbid pathology was 10.2% without differences in gender. The structure of the causes of death in patients with polymorbidity: cardiovascular diseases accounted for 50.8%, oncological diseases 21%, nervous system diseases 7.3%. During the lockdown, an increase in overall mortality by 34.3% was recorded (p 0.05), with an increase in the number of deaths of patients with cardiovascular diseases by 19.5% (p 0.05) (mostly patients with ischemic heart disease). CONCLUSION: An increase in the number of deceased patients with polymorbidity during the lockdown may be due to the limitation of physical activity, of the possibility of examination and consultation by profile specialists. Taking into account the vulnerability of this group of patients, there is an urgent need to develop preventive measures when the situation recurs.


  • Open Access

    TYPE 2 DIABETES MELLITUS – AN AUTOIMMUNE DISEASE?

    by N. S. Asfandiyarova, Асфандиярова Н. C.

    In recent years, the association of type 2 diabetes mellitus (DM) to autoimmune diseases has been discussed. Participation of innate immunity in the development of inflammation in obesity and insulin resistance, which determine the development of type 2 DM is well known. These changes, along with gluco- and lipotoxicity, lead to the destruction of the pancreatic β cells, emergence of autoantigens and development both humoral and cell type autoimmune reactions. The effectiveness of drugs used in the treatment of autoimmune diseases also leads some authors to the conclusion that type 2 diabetes can be referred to autoimmune diseases. However, most researchers believe that the presence of an autoimmune component is a side effect of inflammation and do not consider type 2 diabetes as an autoimmune disease.Alternatively, autoimmune reactions may take part in the pathogenesis of type 2 diabetes because: a viral infection contributes to the development of antiviral immunity, however, in the presence of insulin-cross-reactive antigens, an autoimmune reaction is observed. Most patients with uncompromised immune system, the clone of auto-aggressive cells sensitized to insulin is destroyed. In a small percentage of patients with impaired immune system, insulin-sensitized lymphocytes do not die that leads to destruction of pancreatic islet cells and development of type 1 diabetes. In other patients, on the one hand, the immune system is also unable to remove the cell clone exerting signs of autoaggression, but it tries to suppress this effect by blocking insulin receptors on immunocompetent cells. This maneuver succeeds, and suppression is reversible. However, insulin receptors are abundant not only on sensitized lymphocytes, but also on liver cells, muscles, and adipose tissue. The effect of blocking insulin receptors in insulin-sensitive tissues contributes to the development of primary insulin resistance, which precedes and contributes to the development of obesity. Subsequently, excessive intake of dietary fats results in obesity progression, so that the entire cascade of inflammatory reactions is involved in the pathological process. This, in turn, contributes to the formation of secondary insulin resistance, which accounts for the development of type 2 diabetes and cardiovascular diseases and so on.Type 2 diabetes does not belong to autoimmune diseases, but suppressed autoimmune reactions with respect to insulin play a role in the development of insulin resistance.